Business Standard

Alkem launches novel antibiotic combination for drug-resistant infections

The formulation, to be sold under the Zidavi brans for Rs 2,700 a vial, has been approved by US FDA, European Medicines Agency, and CDSCO

Pharmacy
Premium

Photo: Shutterstock

Sohini Das Mumbai
Mumbai-based drug maker Alkem launched an antibiotic on Monday to treat multiple drug-resistant infections. The firm became the first from India to launch a novel antibiotic combination for treating drug-resistant infections, the company claimed.

The antibiotic, a combination of ceftazidime and avibactam, will be sold under the brand name Zidavi. It is indicated for various ailments such as complicated urinary tract infection. It is available at a price of Rs 2,700 per vial. Zidavi is manufactured in the company’s Sikkim facility.

With the rise in infections caused by carbapenem-resistant Gram-negative organisms in India, there is a need for more effective

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in